Zynex Debt to Equity Ratio 2010-2023 | ZYXI
Current and historical debt to equity ratio values for Zynex (ZYXI) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Zynex debt/equity for the three months ending December 31, 2023 was 1.26.
| Zynex Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-12-31 | $0.09B | $0.05B | 1.97 |
| 2023-09-30 | $0.09B | $0.06B | 1.59 |
| 2023-06-30 | $0.09B | $0.06B | 1.45 |
| 2023-03-31 | $0.05B | $0.06B | 0.72 |
| 2022-12-31 | $0.05B | $0.07B | 0.76 |
| 2022-09-30 | $0.05B | $0.07B | 0.77 |
| 2022-06-30 | $0.05B | $0.07B | 0.73 |
| 2022-03-31 | $0.06B | $0.08B | 0.74 |
| 2021-12-31 | $0.06B | $0.07B | 0.80 |
| 2021-09-30 | $0.03B | $0.06B | 0.43 |
| 2021-06-30 | $0.03B | $0.06B | 0.46 |
| 2021-03-31 | $0.01B | $0.06B | 0.25 |
| 2020-12-31 | $0.02B | $0.06B | 0.27 |
| 2020-09-30 | $0.01B | $0.05B | 0.20 |
| 2020-06-30 | $0.01B | $0.03B | 0.36 |
| 2020-03-31 | $0.01B | $0.02B | 0.43 |
| 2019-12-31 | $0.01B | $0.02B | 0.44 |
| 2019-09-30 | $0.01B | $0.02B | 0.51 |
| 2019-06-30 | $0.01B | $0.01B | 0.55 |
| 2019-03-31 | $0.01B | $0.01B | 0.62 |
| 2018-12-31 | $0.01B | $0.01B | 1.07 |
| 2018-09-30 | $0.00B | $0.01B | 0.45 |
| 2018-06-30 | $0.00B | $0.01B | 0.51 |
| 2018-03-31 | $0.00B | $0.01B | 0.79 |
| 2017-12-31 | $0.00B | $0.01B | 0.82 |
| 2017-09-30 | $0.00B | $0.00B | 2.86 |
| 2017-06-30 | $0.01B | $-0.00B | -3.13 |
| 2017-03-31 | $0.01B | $-0.00B | -2.34 |
| 2016-12-31 | $0.01B | $-0.00B | -2.08 |
| 2016-09-30 | $0.01B | $-0.00B | -2.20 |
| 2016-06-30 | $0.01B | $-0.01B | -1.94 |
| 2016-03-31 | $0.01B | $-0.00B | -1.96 |
| 2015-12-31 | $0.01B | $-0.00B | -1.91 |
| 2015-09-30 | $0.01B | $-0.00B | -2.70 |
| 2015-06-30 | $0.01B | $-0.00B | -3.05 |
| 2015-03-31 | $0.01B | $-0.00B | -3.98 |
| 2014-12-31 | $0.01B | $-0.00B | -6.62 |
| 2014-09-30 | $0.01B | $-0.00B | -6.35 |
| 2014-06-30 | $0.01B | $-0.00B | -6.12 |
| 2014-03-31 | $0.01B | $0.00B | 3.66 |
| 2013-12-31 | $0.01B | $0.01B | 2.55 |
| 2013-09-30 | $0.01B | $0.01B | 1.49 |
| 2013-06-30 | $0.01B | $0.01B | 1.39 |
| 2013-03-31 | $0.01B | $0.01B | 1.10 |
| 2012-12-31 | $0.01B | $0.01B | 1.15 |
| 2012-09-30 | $0.02B | $0.01B | 1.25 |
| 2012-06-30 | $0.01B | $0.01B | 1.28 |
| 2012-03-31 | $0.01B | $0.01B | 1.24 |
| 2011-12-31 | $0.01B | $0.01B | 1.15 |
| 2011-09-30 | $0.01B | $0.01B | 1.21 |
| 2011-06-30 | $0.01B | $0.01B | 1.13 |
| 2011-03-31 | $0.01B | $0.01B | 1.05 |
| 2010-12-31 | $0.01B | $0.01B | 0.92 |
| 2010-09-30 | $0.01B | $0.01B | 0.85 |
| 2010-06-30 | $0.01B | $0.01B | 0.74 |
| 2010-03-31 | $0.01B | $0.01B | 0.82 |
| 2009-12-31 | $0.00B | $0.01B | 0.59 |
| 2009-09-30 | $0.01B | $0.01B | 0.69 |
| 2009-06-30 | $0.01B | $0.01B | 0.93 |
| 2009-03-31 | $0.01B | $0.01B | 1.23 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.388B | $0.184B |
| Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $183.756B | 24.12 |
| Stryker (SYK) | United States | $127.849B | 31.70 |
| Medtronic (MDT) | Ireland | $105.004B | 14.86 |
| Boston Scientific (BSX) | United States | $99.704B | 33.15 |
| EssilorLuxottica (ESLOY) | France | $97.123B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.671B | 0.00 |
| Haleon (HLN) | United Kingdom | $37.031B | 28.96 |
| ResMed (RMD) | United States | $25.568B | 25.56 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.922B | 16.05 |
| Terumo (TRUMY) | Japan | $24.880B | 35.14 |
| Baxter (BAX) | United States | $20.069B | 14.64 |
| Koninklijke Philips (PHG) | Netherlands | $18.712B | 14.93 |
| Insulet (PODD) | United States | $11.642B | 61.12 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.457B | 0.00 |
| Demant (WILYY) | Denmark | $10.001B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.295B | 24.71 |
| BellRing Brands (BRBR) | United States | $7.115B | 38.25 |
| Haemonetics (HAE) | United States | $4.311B | 22.05 |
| Lantheus Holdings (LNTH) | United States | $4.215B | 10.88 |
| Perrigo (PRGO) | Ireland | $4.071B | 11.64 |
| GN Store Nord (GNNDY) | Denmark | $3.675B | 23.80 |
| Prestige Consumer Healthcare (PBH) | United States | $3.378B | 15.97 |
| Envista Holdings (NVST) | United States | $3.367B | 12.80 |
| Green Thumb Industries (GTBIF) | United States | $2.758B | 87.40 |
| Neogen (NEOG) | United States | $2.630B | 25.29 |
| QuidelOrtho (QDEL) | United States | $2.589B | 9.40 |
| ICU Medical (ICUI) | United States | $2.336B | 17.43 |
| TG Therapeutics (TGTX) | United States | $2.134B | 691.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.943B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.858B | 0.00 |
| Owens & Minor (OMI) | United States | $1.836B | 17.62 |
| Agios Pharmaceuticals (AGIO) | United States | $1.631B | 0.00 |
| National Vision Holdings (EYE) | United States | $1.486B | 46.29 |
| InMode (INMD) | Israel | $1.465B | 7.59 |
| LeMaitre Vascular (LMAT) | United States | $1.415B | 46.70 |
| AdaptHealth (AHCO) | United States | $1.253B | 9.43 |
| Warby Parker (WRBY) | United States | $1.189B | 0.00 |
| AtriCure (ATRC) | United States | $1.134B | 0.00 |
| MacroGenics (MGNX) | United States | $1.007B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.757B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.687B | 14.83 |
| BioLife Solutions (BLFS) | United States | $0.686B | 0.00 |
| Evolus (EOLS) | United States | $0.674B | 0.00 |
| Jin Medical (ZJYL) | China | $0.631B | 0.00 |
| Quanterix (QTRX) | United States | $0.602B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.591B | 0.00 |
| Valneva SE (VALN) | France | $0.538B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.533B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.521B | 11.29 |
| PetIQ (PETQ) | United States | $0.469B | 17.50 |
| ZimVie (ZIMV) | United States | $0.417B | 25.55 |
| Biote (BTMD) | United States | $0.411B | 3.91 |
| OraSure Technologies (OSUR) | United States | $0.402B | 6.65 |
| Surmodics (SRDX) | United States | $0.378B | 40.80 |
| Aurora Cannabis (ACB) | Canada | $0.316B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.303B | 30.08 |
| Cerus (CERS) | United States | $0.297B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.272B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.256B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.243B | 14.80 |
| Ayr Wellness (AYRWF) | United States | $0.210B | 0.00 |
| Omeros (OMER) | United States | $0.194B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.189B | 0.00 |
| High Tide (HITI) | Canada | $0.178B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.175B | 0.00 |
| Veru (VERU) | United States | $0.170B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.154B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.138B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.136B | 21.93 |
| Eagleford Energy (GRUSF) | United States | $0.135B | 68.05 |
| InterCure (INCR) | Israel | $0.108B | 18.15 |
| Fonar (FONR) | United States | $0.105B | 8.98 |
| Allurion Technologies (ALUR) | United States | $0.104B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.104B | 0.00 |
| MariMed (MRMD) | United States | $0.101B | 0.00 |
| Safety Shot (SHOT) | United States | $0.097B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 0.00 |
| Brainsway (BWAY) | Israel | $0.084B | 0.00 |
| Chimerix (CMRX) | United States | $0.081B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.073B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.057B | 3.72 |
| Apyx Medical (APYX) | United States | $0.046B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.043B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.043B | 0.00 |
| Bright Green (BGXX) | United States | $0.041B | 0.00 |
| ImmuCell (ICCC) | United States | $0.039B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 14.04 |
| Exagen (XGN) | United States | $0.024B | 0.00 |
| Nephros (NEPH) | United States | $0.021B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.019B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.018B | 0.00 |
| Agape ATP (ATPC) | $0.018B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.010B | 73.36 |
| ProSomnus (OSA) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.008B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |